Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?

Détails

ID Serval
serval:BIB_4FE0F5D00D5E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
Périodique
Endothelium
Auteur(s)
Rüegg C., Dormond O., Foletti A.
ISSN
1062-3329 (Print)
ISSN-L
1026-793X
Statut éditorial
Publié
Date de publication
2002
Volume
9
Numéro
3
Pages
151-160
Langue
anglais
Résumé
Tumor angiogenesis is an essential step in tumor progression and metastasis formation. Suppression of tumor angiogenesis results in the inhibition of tumor growth. Recent evidence indicates that vascular integrins, in particular alpha V beta 3, are important regulators of angiogenesis, including tumor angiogenesis. Integrin alpha V beta 3 antagonists, such as blocking antibodies or peptides, suppress tumor angiogenesis and tumor progression in many preclinical tumor models. The potential therapeutic efficacy of extracellular integrin antagonists in human cancer is currently being tested in clinical trials. Selective disruption of the tumor vasculature by high doses of tumor necrosis factor (TNF) and interferon gamma (IFN-gamma), and the antiangiogenic activity of nonsteroidal anti-inflammatory drugs are associated with the suppression of integrin alpha V beta 3 function and signaling in endothelial cells. Furthermore, expression of isolated integrin cytoplasmic domains disrupts integrin-dependent adhesion, resulting in endothelial cell detachment and apoptosis. These results confirm the critical role of vascular integrins in promoting endothelial cell survival and angiogenesis and suggest that intracellular targeting of integrin function and signaling may be an alternative strategy to extracellular integrin antagonists for the therapeutic inhibition of tumor angiogenesis.
Mots-clé
Angiogenesis Inhibitors/pharmacology, Angiogenesis Inhibitors/therapeutic use, Cell Adhesion Molecules/physiology, Cyclooxygenase 2, Drug Delivery Systems, Endothelium, Vascular/cytology, Endothelium, Vascular/drug effects, Humans, Integrin alphaVbeta3/antagonists & inhibitors, Integrins/antagonists & inhibitors, Interferon-gamma/pharmacology, Isoenzymes/pharmacology, Membrane Proteins, Neoplasms/blood supply, Neoplasms/drug therapy, Neovascularization, Pathologic, Prostaglandin-Endoperoxide Synthases/pharmacology, Signal Transduction/drug effects, Tumor Necrosis Factor-alpha/pharmacology, rho GTP-Binding Proteins/metabolism
Pubmed
Web of science
Création de la notice
28/01/2008 9:36
Dernière modification de la notice
03/03/2018 17:07
Données d'usage